The Efficacy of Induction and Adjuvant Camrelizumab Combined With Chemoradiation for LA-HNSCC

NCT05213884 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

39

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Squamous Cell Carcinoma

Interventions

DRUG: Camrelizumab
DRUG: Concurrent cisplatin chemotherapy
RADIATION: Intensity-modulated radiotherapy (IMRT)

Sponsor

Chongqing University Cancer Hospital